Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Walter Emil Haefeli"'
Autor:
Cornelia Straßner, Cornelia Mahler, Beate Strauß, Ulrich Wehrmann, Katja Krug, Joachim Szecsenyi, Walter Emil Haefeli, Hanna Marita Seidling
Publikováno v:
BMC Geriatrics, Vol 20, Iss 1, Pp 1-9 (2020)
Abstract Background Despite increasing digitalisation the paper-based medication list remains one of the most important instruments for the documentation and exchange of medication-related information. However, even elderly patients with polypharmacy
Externí odkaz:
https://doaj.org/article/2cac5825f291478da11cc2a79d6896c5
Autor:
Fatima Zahra Marok, Jan-Georg Wojtyniak, Laura Maria Fuhr, Dominik Selzer, Matthias Schwab, Johanna Weiss, Walter Emil Haefeli, Thorsten Lehr
Publikováno v:
Pharmaceutics, Vol 15, Iss 2, p 679 (2023)
The antifungal ketoconazole, which is mainly used for dermal infections and treatment of Cushing’s syndrome, is prone to drug–food interactions (DFIs) and is well known for its strong drug–drug interaction (DDI) potential. Some of ketoconazole
Externí odkaz:
https://doaj.org/article/7fb4a21b733e498585cdaaefccde24a2
Autor:
Tim Halling, Steffen Akkermann, Friederike Löffler, Adrian Groh, Ivo Heitland, Walter Emil Haefeli, Johann Bauersachs, Kai G. Kahl, Mechthild Westhoff-Bleck
Publikováno v:
Frontiers in Psychiatry, Vol 12 (2021)
Objective: Innovative operative and interventional procedures have improved survival in congenital heart disease (CHD), and today more than 90% of these children reach adulthood. Consequently, adherence and psychosocial issues are becoming increasing
Externí odkaz:
https://doaj.org/article/39c1891866554132ae6146c76e357597
Autor:
Rafael Perera, Marjan Van Den Akker, Kym I E Snell, Joerg J Meerpohl, Ferdinand M Gerlach, Paul Glasziou, Daniela Küllenberg de Gaudry, Ana Isabel González-González, Jeanet Blom, Christiane Muth, Walter Emil Haefeli, Karin M A Swart, Petra Elders, Henrik Rudolf, Ulrich Thiem, Andreas Daniel Meid, Truc Sophia Dinh, Donna Bosch-Lenders, Hans J Trampisch, Benno Flaig, Ghainsom Kom
Publikováno v:
BMJ Open, Vol 11, Iss 8 (2021)
Objective To explore factors that potentially impact external validation performance while developing and validating a prognostic model for hospital admissions (HAs) in complex older general practice patients.Study design and setting Using individual
Externí odkaz:
https://doaj.org/article/0014ac625b614f349b8b0d9ca196fab9
Autor:
Gzona Bajraktari-Sylejmani, Teresa von Linde, Jürgen Burhenne, Walter Emil Haefeli, Max Sauter, Johanna Weiss
Publikováno v:
Pharmaceutics, Vol 14, Iss 8, p 1610 (2022)
The human peptide transporter hPepT1 (SLC15A1), physiologically transporting dipeptides and tripeptides generated during food digestion, also plays a role in the uptake of small bioactive peptides and peptide-like drugs. Moreover, it might be address
Externí odkaz:
https://doaj.org/article/1b54113a3320446b970efd94b1881b07
Publikováno v:
Pharmaceutics, Vol 13, Iss 6, p 808 (2021)
Interferon-alpha (IFN-α) is suggested to cause pharmacokinetic drug interactions by lowering expression of drug disposition genes through affecting the activities of nuclear factor kappa B (NF-ĸB) and pregnane X receptor (PXR). The time-resolved im
Externí odkaz:
https://doaj.org/article/54b26a1d0ff24fc59b34d79b2b0f354a
Publikováno v:
Pharmaceutics, Vol 6, Iss 4, Pp 632-650 (2014)
Dovitinib (TKI-258) is under development for the treatment of diverse cancer entities. No published information on its pharmacokinetic drug interaction potential is available. Thus, we assessed its interaction with important drug metabolising enzymes
Externí odkaz:
https://doaj.org/article/40b66a0398224556886379758c7dcf1f
Autor:
Johanna Weiss, Melanie Herzog, Sonja König, Caroline Henrike Storch, Nahal Ketabi-Kiyanvash, Walter Emil Haefeli
Publikováno v:
Journal of Pharmacological Sciences, Vol 109, Iss 2, Pp 242-250 (2009)
Efavirenz, an important component of human immunodeficiency virus 1 (HIV-1) therapy, causes substantial drug interactions as an inducer of cytochromes and the transporter ABCB1. So far its effect on the expression of other transporters is unknown. We
Externí odkaz:
https://doaj.org/article/59ff8b576555437f8d5cbe1ca14ea8e2
Publikováno v:
Pharmaceutics, Vol 8, Iss 1, p 5 (2016)
Venetoclax (ABT-199) represents a specific B-cell lymphoma 2 (Bcl-2) inhibitor that is currently under development for the treatment of lymphoid malignancies. So far, there is no published information on its interaction potential with important drug
Externí odkaz:
https://doaj.org/article/b4ea7a5cbbc94c679ee666735cb0f547
Autor:
Annika Elbe, Kathrin Isabelle Foerster, Antje Blank, Peter Rose, Jürgen Burhenne, Walter Emil Haefeli, Gerd Mikus
Publikováno v:
European Journal of Clinical Pharmacology. 78:975-987
Purpose To investigate the suitability of microdosed oral omeprazole for predicting CYP2C19 activity in vivo in combination with simultaneous assessment of CYP3A and CYP2D6 activity using both microdosed midazolam and yohimbine. Methods An open, fixe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be2fb66e4e2946c36e1a0cc7e416396c
https://doi.org/10.1007/s00228-022-03304-3
https://doi.org/10.1007/s00228-022-03304-3